Yaacov-Garbeli Dana

SEC source: 0001178913-26-003953 · zk2635795.xml · derivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 140,000 shares

Expires 2036-05-07

F1 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan).

SEC source: 0001178913-26-002464 · ownership.xml · nonDerivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By A2Z Counseling Ltd.

Disclosed balance after: 171,441

F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026. This grant was awarded to the Reporting Person in lieu of a cash bonus the Reported Person was otherwise entitled to. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026.

F2 · ownership.nature: These shares are owned by A2Z Counseling Ltd. of which the reporting person owns a 33.33% interest and has effective control over voting and disposition of the shares. The reporting person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001178913-25-002410 · ownership.xml · derivative · entry 2

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 130,000 shares

Expires 2035-04-28

F3 · derivative.exercise_date: This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

SEC source: 0001178913-25-002410 · ownership.xml · nonDerivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By A2Z Counseling Ltd.

Disclosed balance after: 113,047

F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.

F2 · ownership.nature: These shares are owned by A2Z Counseling Ltd. of which the reporting person owns a 33.33% interest and has effective control over voting and disposition of the shares. The reporting person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001178913-24-001423 · ownership.xml · derivative · entry 2

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 130,000 shares

Expires 2034-04-19

F2 · derivative.exercise_date: The options vest over a three-year period with 33% of the options vesting on April 19, 2025, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

SEC source: 0001178913-24-001423 · ownership.xml · nonDerivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,731

F1 · price: Represent a grant of stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.

SEC source: 0001178913-24-002392 · ownership.xml · derivative · entry 2

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 130,000 shares

Expires 2034-04-19

F4 · derivative.exercise_date: The options vest over a three-year period with 33% of the options vesting on April 19, 2025, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

SEC source: 0001178913-24-002392 · ownership.xml · nonDerivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By A2Z Counseling Ltd.

Disclosed balance after: 86,731

F1 · price: Represent a grant of stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.

F2 · ownership.direct: On April 23, 2024, the reporting person filed a Form 4 which inadvertently reported that the reporting person's ordinary shares and restricted stock units are held directly.

F3 · ownership.nature: These shares are owned by A2Z Counseling Ltd. of which the reporting person owns a 33.33% interest and has effective control over voting and disposition of the shares. The reporting person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001178913-23-001531 · zk2329588.xml · derivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 190,000 shares

Expires 2033-04-24

F1 · derivative.exercise_date: The options vest over a four-year period with 25% of the options vesting on April 24, 2024, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

SEC source: 0001178913-22-004054 · zk2228766.xml · nonDerivative · entry 2

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By A2Z Counseling Ltd.

Disclosed balance after: 56,580

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.53 to $0.54, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These shares are owned by A2Z Counseling Ltd. of which the Reporting Person's owns a 33.33% interest and has effective control over voting and disposition of the shares. The Reporting Person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001178913-22-004054 · zk2228766.xml · nonDerivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By A2Z Counseling Ltd.

Disclosed balance after: 30,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.50 to $0.54, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These shares are owned by A2Z Counseling Ltd. of which the Reporting Person's owns a 33.33% interest and has effective control over voting and disposition of the shares. The Reporting Person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001178913-22-003370 · ownership.xml · derivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,000 shares

Expires 2031-03-31

F1 · derivative.exercise_date: This grant of options was approved by the Board of Directors of Entera Bio Ltd. (the "Company") on March 31, 2021, subject to approval by the Company's shareholders, which was obtained on September 7, 2022. The options vest over a four-year period that commenced on March 31, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.